The BRCA2 mutation status shapes the immune phenotype of prostate cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The BRCA2 mutation status shapes the immune phenotype of prostate cancer
Authors
Keywords
Prostate cancer, Homologous recombination deficiency, <em class="EmphasisTypeItalic ">BRCA1/2</em>, Tumor-infiltrating lymphocytes, Tumor microenvironment, Immune checkpoint inhibitors
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-24
DOI
10.1007/s00262-019-02393-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
- (2019) Mauro Di Pilato et al. NATURE
- Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
- (2019) Wei Xiong Wen et al. PLoS One
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Blocking PD-1/PD-L1 in Genitourinary Malignancies
- (2018) Matthew C. Dallos et al. CANCER JOURNAL
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
- (2018) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
- (2017) Emma Nolan et al. Science Translational Medicine
- Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
- (2017) Edwin R. Parra et al. Scientific Reports
- Mutations in BRCA2 and taxane resistance in prostate cancer
- (2017) Cathleen Nientiedt et al. Scientific Reports
- PARP inhibition inBRCA2-mutated prostate cancer
- (2016) C. Nientiedt et al. ANNALS OF ONCOLOGY
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology
- (2016) Moritz Jesinghaus et al. GENES CHROMOSOMES & CANCER
- Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system
- (2016) Kelly A Schats et al. HISTOPATHOLOGY
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- High burden of copy number alterations andc-MYCamplification in prostate cancer fromBRCA2germline mutation carriers
- (2015) E. Castro et al. ANNALS OF ONCOLOGY
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions
- (2015) Marie Lundholm et al. Scientific Reports
- Immune Infiltration and Prostate Cancer
- (2015) Amy Strasner et al. Frontiers in Oncology
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer
- (2014) Nora Ness et al. PROSTATE
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Molecular Diagnostic Profiling of Lung Cancer Specimens with a Semiconductor-Based Massive Parallel Sequencing Approach
- (2013) Volker Endris et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
- (2012) Connie Jackaman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Life History of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- CD4 helper T cells, CD8 cytotoxic T cells and FOXP3+ regulatory T cells with respect to lethal prostate cancer
- (2012) Sabina Davidsson et al. MODERN PATHOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
- (2011) Robert A Soslow et al. MODERN PATHOLOGY
- Integrative genomics viewer
- (2011) James T Robinson et al. NATURE BIOTECHNOLOGY
- Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue
- (2010) ALEXANDER VALDMAN et al. APMIS
- Androgen Deprivation Boosts Prostatic Infiltration of Cytotoxic and Regulatory T Lymphocytes and Has No Effect on Disease-Free Survival in Prostate Cancer Patients
- (2010) Carlo Sorrentino et al. CLINICAL CANCER RESEARCH
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
- (2010) K. Wang et al. NUCLEIC ACIDS RESEARCH
- Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients
- (2008) Jean Grant et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started